Other Events ·
Jaguar Health supplements proxy to disclose six-fold increase in stock incentive plan shares
JAGXJaguar Health, Inc.
Jaguar Health filed an 8-K supplement to update its definitive proxy statement for a special meeting of stockholders on November 6, 2026. The filing discloses that the Board approved a six-fold adjustment to the share reserve under the 2014 Stock Incentive Plan following a special one-time dividend of Series R Preferred Stock issued in October. This adjustment ensures the plan's available shares remain approximately 14% of fully diluted outstanding stock as of September 30, 2026. If Proposal 3 to amend and restate the plan is approved by shareholders, the share reserve will increase from 710 to 2,273,154 shares; otherwise, it will rise to 4,260 shares. The adjustment takes effect immediately following the special meeting. Jaguar Health develops and markets pharmaceutical products for gastrointestinal disorders.